News

News

1 2 3 4 5 Next »
1-20 of 2541 results

Alirocumab Reduces LDL-C in Homozygous FH

Mar 30, 2020 by
Chava Chezar-Azerrad and Jason Wermers, CRTonline.org

In patients with homozygous familial hypercholesterolemia (HoFH), treatment with the PCSK9 inhibitor alirocumab was found to significantly reduce low-density lipoprotein cholesterol (LDL-C) levels, as well as other atherogenic lipids and lipoproteins, according to study results presented Monday at the American College of Cardiology Scientific Sessions 2020 virtual conference.

Evinacumab Lowers LDL-C in Homozygous FH

Mar 30, 2020 by
Chava Chezar-Azerrad and Jason Wermers, CRTonline.org

Treatment with evinacumab, an ANGPTL3 inhibitor, in patients with homozygous familial hypercholesterolemia (HoFH), was found to be effective in lowering low-density lipoprotein cholesterol (LDL-C) levels independent of LDL receptor, according to late-breaking trial results presented Monday at the American College of Cardiology Scientific Sessions 2020 virtual conference.

Mavacamten Improves Biomarkers of Myocardial Wall Stress, Injury in Non-Obstructive HCM

Mar 30, 2020 by
Brian C. Case, CRTonline.org

A first-in-class reversible inhibitor of cardiac-specific myosin, mavacamten (mana, MyoKardia Inc.), was associated with significant reductions in N-terminal-pro hormone BNP (NT-proBNP) and cardiac troponin (cTnI), suggesting improved wall stress and reduced myocardial injury in non-obstructive hypertrophic cardiomyopathy (nHCM), according to study results presented Monday at the American College of Cardiology Scientific Sessions 2020 virtual conference.

Edoxaban, Warfarin Show Similar Thromboembolic, Bleeding Prevention After Bioprosthetic Valve Procedures

Mar 30, 2020 by
Jason Wermers, CRTonline.org

The direct oral anticoagulant edoxaban was shown to be noninferior to warfarin in preventing thromboembolism and major bleeding in the first 3 months after surgical bioprosthetic valve implantation or repair, according to study results presented Monday at the American College of Cardiology Scientific Sessions 2020 virtual conference.

10 Years Later, Study Shows Similar Outcomes Between CABG, PCI in Patients with Unprotected Left Main Disease

Mar 30, 2020 by
Brian C. Case, CRTonline.org

In the longest randomized controlled trial to compare drug-eluting stents and coronary artery bypass grafting (CABG) in patients with unprotected left main coronary artery (LMCA) disease, there were no significant differences in the rates of major adverse cardiac or cerebrovascular events, serious composite outcomes, and mortality over 10 years.

Despite More Complex Anatomy, New MitraClip Devices Show More MR Reduction

Mar 30, 2020 by
Brian Forrestal, CRTonline.org

The latest generation of MitraClip devices offers improved reductions in mitral regurgitation (MR) severity at 30 days compared to previous devices, according to study results presented Monday at the American College of Cardiology Scientific Sessions 2020 virtual conference.

Radial Gets a Boost in the OR, Too

Mar 30, 2020 by
Brian Forrestal, CRTonline.org

Patients who underwent coronary artery bypass grafting (CABG) with radial artery grafts showed improved survival and a lower rate of adverse cardiovascular events in comparison with those who underwent bypass surgery with saphenous vein grafts, according to late-breaking trial results presented Monday at the American College of Cardiology Scientific Sessions 2020 virtual conference.

3 Trials Confirm Ticagrelor Reduces Bleeding, Does Not Increase Thromboembolic Events vs. DAPT

Mar 30, 2020 by
Evan Shlofmitz and Jason Wermers, CRTonline.org

Three key late-breaking clinical trials confirmed that ticagrelor without aspirin following percutaneous coronary intervention (PCI) lowers bleeding risk and does not raise thromboembolic risk in comparison with ticagrelor-plus-aspirin therapy across several different types of patients, according to results presented Monday at the American College of Cardiology Scientific Sessions 2020 virtual conference.

Eicosapentaenoic Acid Appears to Drive Icosapent Ethyl’s Cardiovascular Risk Reduction

Mar 30, 2020 by
Jason Wermers, CRTonline.org

The striking reduction in cardiovascular disease risk associated with icosapent ethyl (IPE) seen in the REDUCE-IT trial appears to be the work of the omega-3 fatty acid eicosapentaenoic acid (EPA), according to late-breaking trial results presented Monday at the American College of Cardiology Scientific Sessions 2020 virtual conference.

Radial Gets a Boost in the OR, Too

Mar 30, 2020 by
Brian Forrestal, CRTonline.org

Patients who underwent coronary artery bypass grafting (CABG) with radial artery grafts showed improved survival and a lower rate of adverse cardiovascular events in comparison with those who underwent bypass surgery with saphenous vein grafts, according to late-breaking trial results presented Monday at the American College of Cardiology Scientific Sessions 2020 virtual conference.

Study: Renal Denervation Lowers Blood Pressure Without Medication

Mar 29, 2020 by
Charan Yerasi, crtonline.org

Catheter-based renal denervation is effective in reducing blood pressure in the absence of antihypertensive medications, according to late-breaking trial results presented Sunday at the American College of Cardiology Scientific Sessions 2020 virtual conference.

Rivaroxaban Tops Enoxaparin in Preventing VTE Events After Lower Limb Surgery

Mar 29, 2020 by
Charan Yerasi, crtonline.org

Rivaroxaban was shown to be more effective than enoxaparin in preventing major venous thromboembolic events after nonmajor orthopedic surgery of the lower limbs, according to late-breaking trial results presented Sunday at the American College of Cardiology Scientific Sessions 2020 virtual conference.

Pre-Hospital Sodium Nitrite Does Not Improve Survival in Out-of-Hospital Cardiac Arrest, Study Shows

Mar 29, 2020 by
Brian C. Case, CRTonline.org

The use of sodium nitrite during active resuscitation did not significantly improve survival to hospital admission or to discharge among patients who suffered out-of-hospital cardiac arrest, according to late-breaking trial results presented Sunday at the American College of Cardiology Scientific Sessions 2020 virtual conference.

Rivaroxaban Benefits PAD Patients, With or Without Clopidogrel, Substudy Shows

Mar 29, 2020 by
Charan Yerasi, crtonline.org

A substudy from the VOYAGER PAD trial shows that low-dose rivaroxaban is safe and effective in patients with peripheral arterial disease (PAD) undergoing revascularization, irrespective of clopidogrel use, according to late-breaking trial results presented Sunday at the American College of Cardiology (ACC) Scientific Sessions 2020 virtual conference.

Vein of Marshall Ethanol Infusion Plus Ablation Shows Potential Benefit in Persistent AFib

Mar 29, 2020 by
Nauman Khalid and Jason Wermers, CRTonline.org

Infusing ethanol into the vein of Marshall (VOM), in addition to catheter ablation of persistent atrial fibrillation (AF) reduces the recurrence of AF or atrial tachycardia (AT), reduces AF burden and may reduce the need for repeat procedures, according to study results presented Sunday at the American College of Cardiology Scientific Sessions 2020 virtual conference.

Real-World LAAO Registry Study Shows Better Results Than Trials

Mar 29, 2020 by
Charan Yerasi, CRTonline.org

In-hospital adverse events occurred at lower rates after left atrial appendage occlusion in a registry than were shown in two previous randomized trials, according to late-breaking study results presented Sunday at the American College of Cardiology Scientific Sessions 2020 virtual conference.

TAVR with Self-Expanding Prosthesis Safe, Effective In Low-Risk Patients with Bicuspid Aortic Valves

Mar 29, 2020 by
Brian Forrestal, CRTonline.org

Transcatheter aortic valve replacement (TAVR) using a self-expanding prosthesis is safe in low-risk patients with bicuspid aortic stenosis, according to late-breaking trial results presented Sunday at the American College of Cardiology Scientific Sessions 2020 virtual conference.

Oral Anticoagulation Alone Lowers Bleeding Risk After TAVR in AFib Patients

Mar 29, 2020 by
Chava Chezar-Azerrad and Jason Wermers, CRTonline.org

Patients with atrial fibrillation on oral anticoagulation (OAC) therapy who underwent transcatheter aortic valve replacement (TAVR) and continued treatment with OAC alone had a lower rate of serious bleeding at 1-year follow-up than patients who received OAC plus clopidogrel for 3 months after TAVR, according to late-breaking trial results presented Sunday at the American College of Cardiology Scientific Sessions 2020 virtual conference.

PARTNER 3: TAVR with Balloon-Expandable Valve Holds on to Advantage Over SAVR at 2 Years

Mar 29, 2020 by
Jason Wermers and Jaffar M. Khan, CRTonline.org

Patients at low surgical risk for mortality who underwent transcatheter aortic valve replacement (TAVR) with a balloon-expandable transcatheter heart valve continued to show significantly better outcomes at 2 years than those who underwent surgical aortic valve replacement (SAVR), but the differences between the two groups began to narrow from year 1 to year 2, according to late-breaking trial results presented Sunday at the American College of Cardiology (ACC) Scientific Sessions 2020 virtual conference.

TAVR, SAVR Show Comparable 1-Year Mortality Results in UK TAVI Trial

Mar 29, 2020 by
Jason Wermers and Jaffar M. Khan, CRTonline.org

Transcatheter aortic valve replacement (TAVR) was shown to be non-inferior to surgical aortic valve replacement (SAVR) in terms of mortality in patients age 70 and older deemed to be at increased surgical mortality risk, according to late-breaking trial results presented Sunday at the American College of Cardiology Scientific Sessions 2020 virtual conference.

1 2 3 4 5 Next »
1-20 of 2541 results

CRTonline on Facebook

CRT Meeting

CRTonline on Twitter

Tweets by @CRT_meeting

Explore the Site

Stay Connected

CRT Group Foundation is a not for profit corporation dedicated to providing educational services in the field of cardiology through the website, CRTonline.org and the Cardiovascular Research Technologies (CRT) annual symposium. CRT focuses on the advances and changes in the field of cardiovascular medicine. CRT is designed to provide access to the world’s leading clinicians and the latest research in order to improve practice and treatment outcomes for a variety of health care professionals.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details

* Required
* First Name:
* Last Name:
Member ID:
* Phone Number:
* Email:
* Enter code:

Refine Your Results

Search

Track

Type

Alirocumab Reduces LDL-C in Homozygous FH

Evinacumab Lowers LDL-C in Homozygous FH

Mavacamten Improves Biomarkers of Myocardial Wall Stress, Injury in Non-Obstructive HCM

Edoxaban, Warfarin Show Similar Thromboembolic, Bleeding Prevention After Bioprosthetic Valve Procedures

10 Years Later, Study Shows Similar Outcomes Between CABG, PCI in Patients with Unprotected Left Main Disease

Despite More Complex Anatomy, New MitraClip Devices Show More MR Reduction

Radial Gets a Boost in the OR, Too

3 Trials Confirm Ticagrelor Reduces Bleeding, Does Not Increase Thromboembolic Events vs. DAPT

Eicosapentaenoic Acid Appears to Drive Icosapent Ethyl’s Cardiovascular Risk Reduction

Radial Gets a Boost in the OR, Too

Study: Renal Denervation Lowers Blood Pressure Without Medication

Rivaroxaban Tops Enoxaparin in Preventing VTE Events After Lower Limb Surgery

Pre-Hospital Sodium Nitrite Does Not Improve Survival in Out-of-Hospital Cardiac Arrest, Study Shows

Rivaroxaban Benefits PAD Patients, With or Without Clopidogrel, Substudy Shows

Vein of Marshall Ethanol Infusion Plus Ablation Shows Potential Benefit in Persistent AFib

Real-World LAAO Registry Study Shows Better Results Than Trials

TAVR with Self-Expanding Prosthesis Safe, Effective In Low-Risk Patients with Bicuspid Aortic Valves

Oral Anticoagulation Alone Lowers Bleeding Risk After TAVR in AFib Patients

PARTNER 3: TAVR with Balloon-Expandable Valve Holds on to Advantage Over SAVR at 2 Years

TAVR, SAVR Show Comparable 1-Year Mortality Results in UK TAVI Trial

Explore the Site

Stay Connected

Thank you

* Message:

News

Refine Your Results

Search

Track

Type

CRTonline on Facebook

CRTonline on Twitter

Explore the Site

Stay Connected

Thank you